Like this article?
Get your free daily medical news from Physician's First Watch.
FDA Advisers: Benefits of Newer Oral Contraceptives, Birth Control Patch Outweigh Risks
FDA advisers concluded last week that the benefits of newer, drospirenone-containing oral contraceptives (marketed as Yaz, among others) and the contraceptive patch (Ortho Evra) still outweigh their risks for venous thromboembolism, Reuters reports.
The advisers recommended, however, that the products' labels be simplified to better explain the higher VTE risk they pose compared with older oral contraceptives.
Published in Physician's First Watch December 12, 2011
- VTE risk
matthew weitzel, community health center, 11 Apr 2012 12:53 PM EST
Specialty: Family Medicine
The FDA's remark that the risk of VTE in or after pregnancy is higher than the risk of VTE on... [more]
To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.